{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:32:24Z","timestamp":1769153544029,"version":"3.49.0"},"reference-count":39,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Breast cancer patients with hepatitis B virus (HBV) infection or past HBV infection face heightened risks of chemotherapy-induced hepatotoxicity and HBV reactivation (HBVr). This study aims to evaluate the impact of different HBV serological statuses on the safety of chemotherapy regimens based on paclitaxel throughout the treatment cycle. Methods: This retrospective cohort study analyzed 4562 female breast cancer patients, categorized into three groups: 366 with HBV infection (HBsAg+), 2529 with past HBV infection (HBsAg\u2212\/HBcAb+), and 1667 without HBV infection (control group). The Primary events included liver injury, HBVr, treatment interruption, and laboratory indicator evaluation. Demographic characteristics and periodic laboratory parameters were recorded for within-subject longitudinal analysis. Results: Before chemotherapy, the incidence of liver injury was highest in the HBV-infected group (18.2%), intermediate in the past-infection group (13.2%), and lowest in the control group (12.0%). Throughout chemotherapy, the cumulative incidence of liver injury remained highest in the HBV-infected group (83.2%), compared to the past-infection (71.2%) and control (70.9%) groups. Chemotherapy interruption rates followed a similar gradient: 12.4% in the HBV-infected group, 6.9% in the past-infection group, and 5.5% in the control group. HBV-infected patients had a significantly higher risk of hepatotoxicity than controls during cycle 4 (relative risk 1.56, 95% CI 1.06 to 2.29) and cycle 5 (1.28, 1.09 to 1.75). HBVr occurred in 13 patients with HBV-infected. Conclusions: HBV serological status significantly impacts chemotherapy safety and treatment interruption. Prophylactic antiviral therapy and intensified monitoring during high-risk cycles (cycle 4 and cycle 5) are critical. These findings underscore the necessity of stratified management for HBV-affected breast cancer patients during chemotherapy.<\/jats:p>","DOI":"10.3390\/cancers17213574","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:19:29Z","timestamp":1762348769000},"page":"3574","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Impact of Different Hepatitis B Virus Serological Statuses on the Safety of Different Chemotherapy Regimens in Female Breast Cancer Patients: A Within-Subject Longitudinal Study"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7376-8381","authenticated-orcid":false,"given":"Zhao-Xing","family":"Li","sequence":"first","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Hu","sequence":"additional","affiliation":[{"name":"Information Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bai-Qing","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-Quan","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Yuan","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Chun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pu","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Xuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-Rui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-9001","authenticated-orcid":false,"given":"Ling-Quan","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"World Health Organization (2025, August 10). Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240091672."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_4","unstructured":"Chinese Society of Hepatology, Chinese Medical Association, and Chinese Society of Infectious Diseases, Chinese Medical Association (2022). Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). Zhonghua Gan Zang Bing Za Zhi, 30, 1309\u20131331. (In Chinese)."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s12094-024-03578-2","article-title":"Cross-sectional study of hepatitis B virus infection in female breast cancer patients in China for the first time diagnosed","volume":"27","author":"Li","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Schmidt, M., Vernooij, R., van Nuland, M., Smeijsters, E., Devriese, L., Mohammad, N.H., Hermens, T., Stammers, J., Swart, C., and Egberts, T. (2024). Impaired liver function: Effect on paclitaxel toxicity, dose modifications and overall survival. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-13330-2"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2024.12.004","article-title":"The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines","volume":"82","author":"Wong","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1093\/cid\/ciw043","article-title":"Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy","volume":"62","author":"Gonzalez","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M15-1121","article-title":"Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy","volume":"164","author":"Paul","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e35810","DOI":"10.5812\/hepatmon.35810","article-title":"Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review","volume":"16","author":"Tavakolpour","year":"2016","journal-title":"Hepat. Mon."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and Reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jhep.2020.03.009","article-title":"Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma","volume":"73","author":"Kusumoto","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12072-016-9747-0","article-title":"HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea","volume":"11","author":"Jun","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1097\/CM9.0000000000003278","article-title":"Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022","volume":"137","author":"Sun","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun."},{"key":"ref_17","first-page":"27","article-title":"Progress in adjuvant systemic therapy for breast cancer","volume":"16","author":"Zardavas","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00281-011-0245-0","article-title":"Immunomodulatory effects of cyclophosphamide and implementations for vaccine design","volume":"33","author":"Sistigu","year":"2011","journal-title":"Semin. Immunopathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update","volume":"38","author":"Hwang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"104824","DOI":"10.1016\/j.antiviral.2020.104824","article-title":"Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential","volume":"180","author":"Xia","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rey-Bedon, C., Banik, P., Gokaltun, A., Hofheinz, O., Yarmush, M.L., Uygun, M.K., and Usta, O.B. (2022). CYP450 drug inducibility in NAFLD via an in vitro hepatic model: Understanding drug-drug interactions in the fatty liver. Biomed. Pharmacother., 146.","DOI":"10.1016\/j.biopha.2021.112377"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): A phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2020.23370","article-title":"Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment","volume":"325","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10549-020-05892-z","article-title":"Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients","volume":"184","author":"Mao","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.breast.2022.01.017","article-title":"Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study","volume":"62","author":"Elsamany","year":"2022","journal-title":"Breast"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/jjco\/hyv043","article-title":"Quality of reporting of chemotherapy compliance in randomized controlled trials of breast cancer treatment","volume":"45","author":"Altwairgi","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00268-020-05931-2","article-title":"The Value of Navigators in Breast Cancer Management in a South African Hospital","volume":"45","author":"Farrow","year":"2021","journal-title":"World J. Surg."},{"key":"ref_30","first-page":"714","article-title":"Cardiac safety of neoadjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel\/pertuzumab\/trastuzumab for HER2-positive breast cancer patients","volume":"26","author":"Douganiotis","year":"2021","journal-title":"J. Buon"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-017-4362-x","article-title":"Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer","volume":"166","author":"Yu","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1001\/jama.1986.03380210084030","article-title":"Subclinical hepatic toxicity during combination chemotherapy for breast cancer","volume":"256","author":"Larroquette","year":"1986","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.3748\/wjg.v22.i28.6484","article-title":"Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy","volume":"22","author":"Law","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/annrheumdis-2021-221650","article-title":"Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection","volume":"81","author":"Zhong","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4097\/kja.19049","article-title":"Randomization in clinical studies","volume":"72","author":"Lim","year":"2019","journal-title":"Korean J. Anesthesiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pec.2013.07.012","article-title":"Motivational interviewing in medical care settings: A systematic review and meta-analysis of randomized controlled trials","volume":"93","author":"Lundahl","year":"2013","journal-title":"Patient Educ. Couns."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1109\/TEVC.2018.2884521","article-title":"Bi-phase evolutionary searching for biclusters in gene expression data","volume":"23","author":"Huang","year":"2018","journal-title":"IEEE Trans. Evol. Comput."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1136\/gutjnl-2022-328380","article-title":"Quantification of the hepatitis B virus cccDNA: Evidence-based guidelines for monitoring the key obstacle of HBV cure","volume":"72","author":"Allweiss","year":"2023","journal-title":"Gut"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/gutjnl-2023-330644","article-title":"Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B","volume":"73","author":"Testoni","year":"2023","journal-title":"Gut"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3574\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:34:18Z","timestamp":1762349658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":39,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17213574"],"URL":"https:\/\/doi.org\/10.3390\/cancers17213574","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}